Press Release

Zealand Pharma – $89 Million IPO

August 25, 2017

New York – August 25, 2017 – Cooley advised the underwriters on Zealand Pharma A/S’s $89 million initial public offering of 5,031,250 American Depositary Shares in the United States, which includes the full exercise of the underwriters’ option to purchase additional shares. Capital markets partners Josh Kaufman, Div Gupta and Charlie Kim led the team advising the underwriters. 

Morgan Stanley and Goldman Sachs & Co. LLC acted as joint book-running managers and Guggenheim Securities and Needham & Company acted as co-managers. This IPO marks the first dual listing of a Danish company on NASDAQ and NASDAQ Copenhagen.

Zealand, which now trades on The NASDAQ Global Select Market and NASDAQ Copenhagen under the ticker symbol “ZEAL,” is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.